On April 26, the Supreme Court will hear oral arguments in Amgen Inc. v. Sandoz Inc. and Sandoz Inc. v. Amgen Inc.—cases that could significantly impact makers of biosimilars and branded biologic drugs and how these drugs are brought to market. In this podcast, Finnegan partners Sanya Sukduang and Jonathan R. Davies discuss this historic case and provide a brief overview of the issues the Supreme Court is scheduled to consider.

Please click here to listen to audio